BIOTRON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.057 AUD | +1.79% |
|
-5.00% | -41.24% |
| Apr. 05 | Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25% | MT |
| Feb. 26 | Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.56M 1.03M | Sales 2023 | 1.43M 950K | Capitalization | 23.45M 15.57M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.33M | Net income 2023 | -3M -1.99M | EV / Sales 2022 | 26.4 x |
| Net cash position 2022 | 1.66M 1.1M | Net cash position 2023 | 3.94M 2.62M | EV / Sales 2023 | 13.6 x |
| P/E ratio 2022 |
-15.4
x | P/E ratio 2023 |
-6.11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.79% | ||
| 1 week | -5.00% | ||
| 1 month | -21.92% | ||
| 3 months | -40.00% | ||
| 6 months | -45.71% | ||
| Current year | -41.24% |
1 week
0.05
0.06
1 month
0.050.08
Current year
0.050.12
1 year
0.020.13
3 years
0.020.13
5 years
0.020.19
10 years
0.010.45
| Managers | Title | Age | Since |
|---|---|---|---|
Michelle Miller
CEO | Chief Executive Officer | - | 02-06-20 |
Stephen Becker
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-16 |
| Corporate Secretary | 67 | 99-02-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Thomas
BRD | Director/Board Member | 79 | 12-03-06 |
Michael Hoy
CHM | Chairman | 75 | 00-02-06 |
Michelle Miller
CEO | Chief Executive Officer | - | 02-06-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 0.057 | +1.79% | 233 541 |
| 24-05-14 | 0.056 | -3.45% | 326,765 |
| 24-05-13 | 0.058 | +5.45% | 431,084 |
| 24-05-10 | 0.055 | -5.17% | 730,945 |
| 24-05-09 | 0.058 | -3.33% | 420,553 |
Delayed Quote Australian S.E., May 15, 2024 at 01:13 am EDT
More quotes
Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyâs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -41.24% | 33.46M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.70% | 21.25B | |
| -6.03% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +5.10% | 13.94B | |
| +37.57% | 12.54B |
- Stock Market
- Equities
- BIT Stock
